The fatty acid oxidation product 15-A 3t-Isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation

Journal of Neurochemistry

Volumn 119, Issue 3, 2011, Pages 604-616

  Brooks, Joshua D ^a   Musiek, Erik S ^a   Koestner, Tyler R ^a   Stankowski, Jeannette N ^a,b   Howard, Jocelyn R ^a   Brunoldi, Enrico M ^c   Porta, Alessio ^c   Zanoni, Giuseppe ^c   Vidari, Giovanni ^b   Morrow, Jason D ^a   Milne, Ginger L ^a   McLaughlin, Bethann ^a,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PAVIA   (Italy)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; cytoprotection; eicosapentaenoic acid; inflammation; oxidative stress

Indexed keywords

15 A3T ISOPROSTANE; ANTIINFLAMMATORY AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CARBONYL DERIVATIVE; CYCLOOXYGENASE 2; I KAPPA KINASE; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; ISOPROSTANE DERIVATIVE; PHOSPHOTRANSFERASE; THIOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL NUCLEUS; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; FATTY ACID OXIDATION; GENETIC TRANSCRIPTION; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; FATTY ACIDS; ISOPROSTANES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NF-KAPPA B; OXIDATION-REDUCTION; OXIDATIVE STRESS; TRANSCRIPTION, GENETIC;

EID: 80054058222     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07422.x     Document Type: Article

References (64)

1. Atsmon J., Freeman M. L., Meredith M. J., Sweetman B. J., and, Roberts 2nd L. J., (1990) Conjugation of 9-deoxy-delta 9,delta 12(E)-prostaglandin D2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res., 50, 1879-1885. (Pubitemid 20098838)
2. Babcock T. A., Novak T., Ong E., Jho D. H., Helton W. S., and, Espat N. J., (2002) Modulation of lipopolysaccharide-stimulated macrophage tumor necrosis factor-alpha production by omega-3 fatty acid is associated with differential cyclooxygenase-2 protein expression and is independent of interleukin-10. J. Surg. Res., 107, 135-139. (Pubitemid 35191824)
3. Barnham K. J., Masters C. L., and, Bush A. I., (2004) Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov., 3, 205-214.
4. Bazan N. G., Colangelo V., and, Lukiw W. J., (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediators, 68-9, 197-210. (Pubitemid 35247397)
5. Blackwell T. S., Yull F. E., Chen C. L., Venkatakrishnan A., Blackwell T. R., Hicks D. J., Lancaster L. H., Christman J. W., and, Kerr L. D., (2000) Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation. Am. J. Respir. Crit. Care Med., 162, 1095-1101.
6. Bond M., Fabunmi R. P., Baker A. H., and, Newby A. C., (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett., 435, 29-34. (Pubitemid 28432009)
7. Brach M. A., Henschler R., Mertelsmann R. H., and, Herrmann F., (1991) Regulation of M-CSF expression by M-CSF: role of protein kinase C and transcription factor NF kappa B. Pathobiology, 59, 284-288.
8. Brand K., Page S., Rogler G., et al. (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest., 97, 1715-1722. (Pubitemid 26105480)
9. Brooks J. D., Milne G. L., Yin H., Sanchez S. C., Porter N. A., and, Morrow J. D., (2008a) Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem., 283, 12043-12055.
10. Brooks J. D., Sanchez S. C., Milne G. L., McLaughlin B. A., and, Morrow J. D., (2008b) Highly reactive cyclopentenone isoprostanes derived from eicosapentaenoic acid exert potent anti-inflammatory effects through inhibition of NF kappa B signaling. Free Radic. Biol. Med., 45, S133-S133.
11. Brown J. E., Zeiger S. L. H., Hettinger J. C., Brooks J. D., Holt B., Morrow J. D., Musiek E. S., Milne G., and, McLaughlin B., (2010) Essential role of the redox-sensitive kinase p66shc in determining energetic and oxidative status and cell fate in neuronal preconditioning. J. Neurosci., 30, 5242-5252.
12. Burleigh M. E., Babaev V. R., Oates J. A., et al. (2002) Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 105, 1816-1823. (Pubitemid 34408892)
13. Calder P. C., (2006) Use of fish oil in parenteral nutrition: Rationale and reality. Proc. Nutr. Soc., 65, 264-277. (Pubitemid 46323841)
14. Calder P. C., (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol. Nutr. Food Res., 52, 885-897.
15. Chaudhary A., Mishra A., and, Sethi S., (2004) Oxidized omega-3 fatty acids inhibit pro-inflammatory responses in glomerular endothelial cells. Nephron. Exp. Nephrol., 97, e136-e145.
16. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and, Evans R. M., (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med., 7, 48-52. (Pubitemid 32095641)
17. Chen Y., Morrow J. D., and, Roberts L. J., II, (1999) Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem., 274, 10863-10868.
18. Chen C. T., Liu Z., and, Bazinet R. P., (2011) Rapid de-esterification and loss of eicosapentaenoic acid from rat brain phospholipids: an intracerebroventricular study. J. Neurochem., 116, 363-373.
19. Chene G., Dubourdeau M., Balard P., et al. (2007) n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim. Biophys. Acta, 1771, 576-589. (Pubitemid 46680522)
20. Chun K. S., and, Surh Y. J., (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol., 68, 1089-1100.
21. Cleland J. G., Freemantle N., Coletta A. P., and, Clark A. L., (2006) Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail., 8, 105-110. (Pubitemid 43012109)
22. Connor W. E., (1997) The beneficial effects of omega-3 fatty acids: cardiovascular disease and neurodevelopment. Curr. Opin. Lipidol., 8, 1-3.
23. Connors S. L., Levitt P., Matthews S. G., Slotkin T. A., Johnston M. V., Kinney H. C., Johnson W. G., Dailey R. M., and, Zimmerman A. W., (2008) Fetal mechanisms in neurodevelopmental disorders. Pediatr. Neurol., 38, 163-176. (Pubitemid 351221226)
24. Cox B. E., Milne G. L., Brooks J. D., Sanchez S. C., Yin H. Y., and, Morrow J. D., (2008) Formation of novel D-ring and E-ring isoprostanes-like compounds in vivo and in vitro from the oxidation of eicosapentaenoic acid. Free Radic. Biol. Med., 45, S69-S69.
25. Cox B. E., Brooks J. D., Pfister S. L., Morrow J. D., Yin H. Y., Milne G. L., and, Roberts L. J., (2009) Comparison studies on the biological activity of 3-series isoprostanes derived from eicosapentaenoic acid and 2-series isoprostanes derived from arachidonic acid. Free Radic. Biol. Med., 47, S72-S72.
26. Davis T. A., Gao L., Yin H., Morrow J. D., and, Porter N. A., (2006) In vivo and in vitro lipid peroxidation of arachidonate esters: the effect of fish oil omega-3 lipids on product distribution. J. Am. Chem. Soc., 128, 14897-14904. (Pubitemid 44851629)
27. De Caterina R., and, Zampolli A., (2001) n-3 fatty acids: antiatherosclerotic effects. Lipids, 36 (Suppl), S69-S78. (Pubitemid 34106212)
28. De Caterina R., Cybulsky M. I., Clinton S. K., Gimbrone M. A., Jr, and, Libby P., (1994) The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler. Thromb., 14, 1829-1836.
29. Fam S. S., Murphey L. J., Terry E. S., et al. (2002) Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem., 277, 36076-36084.
30. Ferreira V., van Dijk K. W., Groen A. K., Vos R. M., van der Kaa J., Gijbels M. J., Havekes L. M., and, Pannekoek H., (2007) Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis, 192, 283-290. (Pubitemid 46726329)
31. Gao L., Yin H., Milne G. L., Porter N. A., and, Morrow J. D., (2006) Formation of F-ring isoprostane-like compounds (F3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem., 281, 14092-14099. (Pubitemid 43848336)
32. Gao L., Wang J., Sekhar K. R., et al. (2007) Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J. Biol. Chem., 282, 2529-2537. (Pubitemid 47076775)
33. Glass C. K., Saijo K., Winner B., Marchetto M. C., and, Gage F. H., (2010) Mechanisms underlying inflammation in neurodegeneration. Cell, 140, 918-934.
34. Gloire G., Legrand-Poels S., and, Piette J., (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol., 72, 1493-1505. (Pubitemid 44666727)
35. Gu L., Okada Y., Clinton S. K., Gerard C., Sukhova G. K., Libby P., and, Rollins B. J., (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 2, 275-281. (Pubitemid 128373654)
36. Hansson G. K., Robertson A. K., and, Soderberg-Naucler C., (2006) Inflammation and atherosclerosis. Annu. Rev. Pathol., 1, 297-329.
37. Horrocks L. A., and, Yeo Y. K., (1999) Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res., 40, 211-225. (Pubitemid 29435720)
38. Karin M., and, Ben-Neriah Y., (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol., 18, 621-663. (Pubitemid 30365393)
39. Khalfoun B., Thibault F., Watier H., Bardos P., and, Lebranchu Y., (1997) Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv. Exp. Med. Biol., 400B, 589-597.
40. Kris-Etherton P. M., Harris W. S., and, Appel L. J., (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106, 2747-2757. (Pubitemid 35364932)
41. Lee J. Y., Plakidas A., Lee W. H., Heikkinen A., Chanmugam P., Bray G., and, Hwang D. H., (2003) Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid Res., 44, 479-486. (Pubitemid 37279695)
42. Li H., Ruan X. Z., Powis S. H., Fernando R., Mon W. Y., Wheeler D. C., Moorhead J. F., and, Varghese Z., (2005) EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int., 67, 867-874. (Pubitemid 41623311)
43. Li Q., Tan L., Wang C., Li N., Li Y., Xu G., and, Li J., (2006) Polyunsaturated eicosapentaenoic acid changes lipid composition in lipid rafts. Eur. J. Nutr., 45, 144-151.
44. McLaughlin B. A., Hartnett K. A., Erhardt J. A., Legos J. J., White R. F., Barone F. C., and, Aizenman E., (2003) Caspase 3 activation is essential for neuroprotection in ischemic preconditioning. Proc. Natl Acad. Sci. USA, 100, 715-720. (Pubitemid 36126118)
45. Milne G. L., Zanoni G., Porta A., Sasi S., Vidari G., Musiek E. S., Freeman M. L., and, Morrow J. D., (2004) The cyclopentenone product of lipid peroxidation, 15-A2t-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione. Chem. Res. Toxicol., 17, 17-25. (Pubitemid 38134056)
46. Mishra A., Chaudhary A., and, Sethi S., (2004) Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. Arterioscler. Thromb. Vasc. Biol., 24, 1621-1627. (Pubitemid 39180885)
47. Montine K. S., Quinn J. F., Zhang J., Fessel J. P., Roberts L. J., Morrow J. D., and, Montine T. J., (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids, 128, 117-124. (Pubitemid 38167381)
48. Mori M., Itabe H., Higashi Y., Fujimoto Y., Shiomi M., Yoshizumi M., Ouchi Y., and, Takano T., (2001) Foam cell formation containing lipid droplets enriched with free cholesterol by hyperlipidemic serum. J. Lipid Res., 42, 1771-1781. (Pubitemid 33116708)
49. Morrow J. D., and, Roberts L. J., II, (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol., 300, 3-12. (Pubitemid 28500576)
50. Mozaffarian D., (2007) JELIS, fish oil, and cardiac events. Lancet, 369, 1062-1063. (Pubitemid 46483647)
51. Musiek E. S., Gao L., Milne G. L., et al. (2005) Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J. Biol. Chem., 280, 35562-35570. (Pubitemid 41532748)
52. Musiek E. S., Brooks J. D., Joo M., et al. (2008) Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J. Biol. Chem., 283, 19927-19935.
53. Perez-Sala D., Cernuda-Morollon E., Pineda-Molina E., and, Canada F. J., (2002) Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann. N Y Acad. Sci., 973, 533-536. (Pubitemid 36125064)
54. Phillis J. W., Horrocks L. A., and, Farooqui A. A., (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res. Rev., 52, 201-243. (Pubitemid 44291802)
55. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and, Santoro M. G., (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature, 403, 103-108. (Pubitemid 30038530)
56. Saito Y., Yokoyama M., Origasa H., et al. (2008) Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis, 300, 135-140.
57. Simopoulos A. P., (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr., 21, 495-505. (Pubitemid 36026261)
58. Vallve J. C., Uliaque K., Girona J., Cabre A., Ribalta J., Heras M., and, Masana L., (2002) Unsaturated fatty acids and their oxidation products stimulate CD36 gene expression in human macrophages. Atherosclerosis, 164, 45-56. (Pubitemid 34765636)
59. Wilson S. H., Caplice N. M., Simari R. D., Holmes D. R., Jr, Carlson P. J., and, Lerman A., (2000) Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis, 148, 23-30.
60. de Winther M. P., Kanters E., Kraal G., and, Hofker M. H., (2005) Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 25, 904-914. (Pubitemid 40627833)
61. Yokoyama M., and, Origasa H., (2003) Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am. Heart J., 146, 613-620. (Pubitemid 37281704)
62. Yokoyama M., Origasa H., Matsuzaki M., et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 369, 1090-1098. (Pubitemid 46483662)
63. Zanoni G., Porta A., and, Vidari G., (2002) First total synthesis of A(2) isoprostane. J. Org. Chem., 67, 4346-4351.
64. Zhao L., and, Funk C. D., (2004) Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med., 14, 191-195. (Pubitemid 38942827)